Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 875,875,520
  • Shares Outstanding, K 944,819
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.51
  • Price/Sales 13.10
  • Price/Cash Flow 35.96
  • Price/Book 32.21

Options Overview Details

View History
  • Implied Volatility 45.90% (+0.21%)
  • Historical Volatility 31.08%
  • IV Percentile 96%
  • IV Rank 91.50%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 6) 28.94 (3.12%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 36,109
  • Volume Avg (30-Day) 37,023
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 354,061
  • Open Int (30-Day) 324,268
  • Expected Range 898.09 to 955.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $7.52
  • Number of Estimates 7
  • High Estimate $8.56
  • Low Estimate $6.90
  • Prior Year $3.34
  • Growth Rate Est. (year over year) +125.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
877.11 +5.69%
on 03/27/26
976.68 -5.08%
on 04/01/26
-3.32 (-0.36%)
since 03/17/26
3-Month
877.11 +5.69%
on 03/27/26
1,114.00 -16.78%
on 02/04/26
-111.37 (-10.73%)
since 01/16/26
52-Week
623.78 +48.61%
on 08/08/25
1,133.95 -18.25%
on 01/08/26
+87.07 (+10.37%)
since 04/17/25

Most Recent Stories

More News
3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

NVO : 40.52 (-1.00%)
OZEM : 32.38 (+1.28%)
LLY : 927.03 (+2.55%)
GPCR : 50.75 (-5.14%)
THNR : 25.05 (+0.72%)
Lilly confirms date and conference call for first-quarter 2026 financial results announcement

INDIANAPOLIS , April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call...

LLY : 927.03 (+2.55%)
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events

LLY : 927.03 (+2.55%)
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm

LLY : 927.03 (+2.55%)
1 Profitable Stock to Own for Decades and 2 That Underwhelm

1 Profitable Stock to Own for Decades and 2 That Underwhelm

HAL : 37.15 (-2.62%)
LLY : 927.03 (+2.55%)
POOL : 227.62 (+0.88%)
What to Expect From Eli Lilly's Next Quarterly Earnings Report

Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings.

XLV : 148.80 (+1.49%)
$SPX : 7,126.06 (+1.20%)
LLY : 927.03 (+2.55%)
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide

LLY : 927.03 (+2.55%)
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.

CEG : 296.21 (-0.98%)
NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
CCL : 29.22 (+6.99%)
2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off

2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off

TTD : 22.47 (-1.27%)
LLY : 927.03 (+2.55%)
MCHP : 78.76 (+2.46%)
The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

NVDA : 201.68 (+1.68%)
$SPX : 7,126.06 (+1.20%)
CNTA : 39.66 (+0.33%)
LLY : 927.03 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 944.27
2nd Resistance Point 937.13
1st Resistance Point 932.08
Last Price 927.03
1st Support Level 919.89
2nd Support Level 912.75
3rd Support Level 907.70

See More

52-Week High 1,133.95
Fibonacci 61.8% 939.07
Last Price 927.03
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.